Find Federal Grants
NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
National Institutes of Health · RFA-DC-24-007
Civil Society and Media Activity
Uzbekistan USAID-Tashkent · 72012224RFA00001
Fiscal Year (FY) 2023 through FY 2026 Bridge Investment Program, Planning and Bridge Project Grants
DOT Federal Highway Administration · 693JJ324NF00006
Economic Development Administration · EDA-RECOMPETEPHASE2-2023
Strengthening Capacity of Central Asia and Eastern Europe Countries to Implement Sustainable and Effective HIV/AIDS Prevention, Care, and Treatment and Health Security Programs under PEPFAR
Centers for Disease Control - CGH · CDC-RFA-GH-24-0069
Office of Procurement Operations - Grants Division · DHS-24-USSS-142-NCFI-0001
Bureau of Democracy Human Rights and Labor · SFOP0010165
Office on Violence Against Women · O-OVW-2024-171930
2023 Inflation Reduction Act Climate Ready Workforce for Coastal States, Tribes, and Territories Competition
DOC NOAA - ERA Production · NOAA-OAR-SG-2024-2007783
National Institutes of Health · PAR-23-315
U.S. Mission to Paraguay · OFOP0001272
Institute of Museum and Library Services · 21MP-FY24
Health Resources and Services Administration · HRSA-24-104
FY24 Department of Navy (DON) Science, Technology, Engineering, and Mathematics (STEM) Education and Workforce Program
Office of Naval Research · N0001424SF003
National Park Service · P24AS00516
Fiscal Year 2024 Safeguarding Tomorrow through Ongoing Risk Mitigation Revolving Loan Fund Program
Department of Homeland Security - FEMA · DHS-24-STORM-139-00-01
NASA Headquarters · NNH23ZDA001N-IIP
Request for Information (RFI) for Potential Partners for Planned Knowledge, Monitoring, Evidence, Learning, and Research Activity
Jordan USAID-Amman · RFI-278-24-PRO-KMELR
U.S. Mission to Zambia · PAS-LUSAKA-AFCP-FY2024
Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)
National Institutes of Health · RFA-DA-25-028